Cowen and Company reiterated their outperform rating on shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) in a research report sent to investors on Wednesday morning. They currently have a $64.00 price objective on the stock.
SRPT has been the topic of a number of other research reports. Janney Montgomery Scott raised shares of Sarepta Therapeutics from a neutral rating to a buy rating and lifted their price target for the company from $30.00 to $65.00 in a research report on Monday, September 19th. William Blair reissued an outperform rating and issued a $88.00 price target on shares of Sarepta Therapeutics in a research report on Sunday. Jefferies Group reissued an underperform rating and issued a $7.00 price target on shares of Sarepta Therapeutics in a research report on Saturday, June 25th. Robert W. Baird reissued an outperform rating and issued a $23.00 price target on shares of Sarepta Therapeutics in a research report on Monday, July 18th. Finally, JMP Securities restated an underperform rating and issued a $10.00 price objective on shares of Sarepta Therapeutics in a research note on Sunday, July 24th. One analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Sarepta Therapeutics currently has a consensus rating of Buy and a consensus target price of $58.12.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded down 0.02% during mid-day trading on Wednesday, hitting $62.34. 278,178 shares of the stock traded hands. Sarepta Therapeutics has a 12-month low of $8.00 and a 12-month high of $63.73. The firm’s 50 day moving average price is $39.01 and its 200-day moving average price is $24.87. The stock’s market cap is $2.99 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same quarter in the previous year, the company earned ($0.87) EPS. Analysts predict that Sarepta Therapeutics will post ($4.16) earnings per share for the current year.
In other Sarepta Therapeutics news, SVP David T. Howton sold 7,000 shares of the business’s stock in a transaction dated Thursday, September 22nd. The stock was sold at an average price of $60.00, for a total transaction of $420,000.00. Following the completion of the sale, the senior vice president now directly owns 28,453 shares of the company’s stock, valued at approximately $1,707,180. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Edward M. Md Kaye sold 24,557 shares of the business’s stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of $30.00, for a total value of $736,710.00. Following the sale, the chief executive officer now directly owns 76,983 shares of the company’s stock, valued at $2,309,490. The disclosure for this sale can be found here. Company insiders own 10.90% of the company’s stock.
A number of hedge funds have recently made changes to their positions in SRPT. State Street Corp raised its position in Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock valued at $48,168,000 after buying an additional 865,658 shares during the last quarter. Franklin Resources Inc. bought a new position in Sarepta Therapeutics during the first quarter valued at about $13,506,000. A.R.T. Advisors LLC bought a new position in Sarepta Therapeutics during the first quarter valued at about $7,461,000. Eagle Asset Management Inc. bought a new position in Sarepta Therapeutics during the second quarter valued at about $6,756,000. Finally, Emerald Mutual Fund Advisers Trust bought a new position in Sarepta Therapeutics during the second quarter valued at about $4,712,000. 65.29% of the stock is owned by hedge funds and other institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.